UPDATES & NEWS
Your gateway to the latest developments and insights from our team of experts in cutting-edge chemistry. Here, you’ll find updates on our key milestones, industry partnerships, and ongoing research efforts.
Liverpool ChiroChem and Veritas In Silico Enter into a Collaboration Development & Commercialisation Agreement for mRNA-targeted Small Molecule Drugs
Liverpool ChiroChem Ltd. (hereinafter referred to as “LCC”) and Veritas In Silico Inc. (hereinafter referred to as “VIS”) announce that LCC and VIS have entered into a Collaboration Development & Commercialisation Agreement today to jointly generate mRNA-targeted...
LCC is transitioning to a hub-and-spoke biotech company
LCC is transitioning from a CRO to a hub-and-spoke biotech company, generating small molecule lead candidate assets against oncology and rare disease targets. LCC built and validated its chemistry platform over 10 years via successful delivery across multiple target...
LCC and Veritas In Silico Form Strategic Partnership
Liverpool ChiroChem Ltd. (LCC) and Veritas In Silico Inc. (VIS) have agreed to form a strategic partnership that combines CC’s chemistry platform with VIS’ unique biology platform ibVIS®. This partnership is aiming to generate the first-in-class and best-in-class assets of small molecule against undisclosed mRNA targets.
Appointment of Dr Steven Powell as New Non-Executive Chair
LCC has announced that Dr Steven Powell has been appointed to the Board of the Company as a Non-Executive Chair. Steven is a dedicated life-science professional with a proven track record; he has supported several companies' developments and exits over an extensive...
Dr Gary Tilbrook announced as New Chief Scientific Officer
LCC has announced that Dr Gary Tilbrook has been appointed to the Board of the Company as a Chief Scientific Officer. Gary is an experienced medicinal chemist with an in-depth knowledge of drug discovery and development, built from working within the biotech sector...
LCC relocate to new labs
After eight successful years of operating within the Chemistry Department at the University of Liverpool, LCC has now made an exciting move to an independent laboratory space at the Heath Business and Technical Park in Runcorn. This relocation marks a significant...
Appointment of Dr Steven Powell as New Non-Executive Chair
LCC has announced that Dr Steven Powell has been appointed to the Board of the Company as a Non-Executive Chair. Steven is a dedicated life-science professional with a proven track record; he has supported several companies' developments and exits over an extensive...
Dr Gary Tilbrook announced as New Chief Scientific Officer
LCC has announced that Dr Gary Tilbrook has been appointed to the Board of the Company as a Chief Scientific Officer. Gary is an experienced medicinal chemist with an in-depth knowledge of drug discovery and development, built from working within the biotech sector...
Liverpool ChiroChem and Veritas In Silico Enter into a Collaboration Development & Commercialisation Agreement for mRNA-targeted Small Molecule Drugs
Liverpool ChiroChem Ltd. (hereinafter referred to as “LCC”) and Veritas In Silico Inc. (hereinafter referred to as “VIS”) announce that LCC and VIS have entered into a Collaboration Development & Commercialisation Agreement today to jointly generate mRNA-targeted...
LCC is transitioning to a hub-and-spoke biotech company
LCC is transitioning from a CRO to a hub-and-spoke biotech company, generating small molecule lead candidate assets against oncology and rare disease targets. LCC built and validated its chemistry platform over 10 years via successful delivery across multiple target...
LCC and Veritas In Silico Form Strategic Partnership
Liverpool ChiroChem Ltd. (LCC) and Veritas In Silico Inc. (VIS) have agreed to form a strategic partnership that combines CC’s chemistry platform with VIS’ unique biology platform ibVIS®. This partnership is aiming to generate the first-in-class and best-in-class assets of small molecule against undisclosed mRNA targets.
Appointment of Dr Steven Powell as New Non-Executive Chair
LCC has announced that Dr Steven Powell has been appointed to the Board of the Company as a Non-Executive Chair. Steven is a dedicated life-science professional with a proven track record; he has supported several companies' developments and exits over an extensive...
Dr Gary Tilbrook announced as New Chief Scientific Officer
LCC has announced that Dr Gary Tilbrook has been appointed to the Board of the Company as a Chief Scientific Officer. Gary is an experienced medicinal chemist with an in-depth knowledge of drug discovery and development, built from working within the biotech sector...
LCC relocate to new labs
After eight successful years of operating within the Chemistry Department at the University of Liverpool, LCC has now made an exciting move to an independent laboratory space at the Heath Business and Technical Park in Runcorn. This relocation marks a significant...